Recombinant Human CD20 Protein，His

CD20 is a transmembrane protein primarily expressed on the surface of B lymphocytes and plays a crucial role in B cell development and activation. Its unique expression pattern makes it an attractive target for therapeutic interventions in various B cell-related diseases, particularly in hematological malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. The development of anti-CD20 monoclonal antibodies, such as Rituximab, has revolutionized the treatment landscape for these conditions, significantly improving patient outcomes. However, challenges such as resistance to therapy and the need for more effective therapeutic strategies have prompted ongoing research into CD20. Recombinant CD20 protein has emerged as a valuable tool for studying the biology of B cells and the mechanisms of action of anti-CD20 therapies. By producing CD20 in recombinant systems, researchers can investigate its structural and functional properties, explore the dynamics of B cell signaling, and develop novel therapeutic agents that can enhance the efficacy of CD20-targeted treatments. Additionally, recombinant CD20 can serve as a basis for the design of bispecific antibodies and other innovative modalities aimed at improving the specificity and effectiveness of B cell-targeting therapies, thus holding promise for advancing treatment options for patients with B cell malignancies. Overall, the research surrounding recombinant CD20 protein is pivotal in understanding B cell biology and developing next-generation immunotherapies.